Table 2.

Factors related to outcome in the study population

Characteristics	Survivors (N = 13)	Not survivors (N = 38)	P	OR (95% CI)	P
Male sex, n (%)	12 (92.3)	35 (92.1)	>0.999
Median (IQR) age (years)	62 (57.5–69)	71 (62–76)	0.102	0.970 (0.924–1.018)	0.218
Interval between symptoms onset and ICU admission, median (IQR) days	11 (10–13)	9 (7.75–11.25)	0.042	1.000 (0.879–1.139)	0.995
Comorbidities, n (%)
ischaemic heart disease	1 (7.7)	6 (15.8)	0.662
congestive heart failure	0 (0)	4 (10.5)	0.561
COPD	0	3 (7.9)	0.561
diabetes mellitus	2 (15.4)	5 (13.2)	0.950
chronic kidney disease	0	4 (10.5)	0.561
hypertension	9 (69.2)	19 (50)	0.379
Median (IQR) Charlson Comorbidity Index	2 (1–3)	3 (1.75–4)	0.045	1.184 (1.027–1.365)	0.020
Laboratory values
mean ± SD WBC/mm3	9158±3180	9276±3642	0.918
mean ± SD neutrophils/mm3	7838±3175	8109±3436	0.804
median (IQR) lymphocytes/mm3	600 (500–900)	600 (375–900)	0.514
median (IQR) platelets × 103/mm3	216 (170–269)	184 (132–238)	0.041	1 (1.000–1.000)	0.304
median (IQR) creatinine (mg/dL)	0.91 (0.85–1.08)	1.11 (0.84–1.56)	0.336
median (IQR) ALT (U/L)	48 (28.5–79)	44.5 (33–57.2)	0.673
median (IQR) AST (U/L)	51 (26.5–64.5)	33 (24.5–41.7)	0.187	1.001 (0.998–1.004)	0.524
median (IQR) total bilirubin (mg/dL)	1.2 (0.8–1.35)	0.8 (0.6–1.25)	0.182	1.358 (0.777–2.375)	0.283
median (IQR) LDH (U/L)	457 (330–545)	504 (388–575)	0.310
mean ± SD CRP (mg/dL)	24.8±14.3	19.1±10.6	0.135	0.999 (0.967–1.031)	0.936
Median (IQR) SOFA score at admission	4 (3.5–5)	5 (4–6)	0.488
CRRT, n (%)	2 (15.4)	23 (60.5)	0.013	0.837 (0.409–1.714)	0.627
Concomitant therapies, n (%)
hydroxychloroquine	10 (76.9)	23 (60.5)	0.336
lopinavir/ritonavir	8 (61.5)	21 (55.3)	0.944
tocilizumab	5 (38.5)	4 (10.5)	0.036	2.074 (0.714–6.024)	0.180
remdesivir	11 (84.6)	14 (36.8)	0.008	3.506 (1.768–6.954)	<0.001